Salarius Pharmaceuticals Inc (SLRX) Actualités

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Patient Enrollment Resumed in the Investigator-initiated Phase 1/2 Clinical Trial of Seclidemstat in...

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses

Company implementing a series of cost-savings measures designed to extend Salarius’ expected cash runway into...

Salarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein Degraders

Expands IP portfolio with composition-of-matter protection into 2039 for novel molecular glues Protein...

Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment

HOUSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) announces that the...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program

FDA briefing included new Ewing sarcoma clinical data from ongoing investigation where 60% of first-relapse...

Form SC 13D - General statement of acquisition of beneficial ownership

Form 8-K - Current report

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update

FDA removed partial clinical hold for Ewing sarcoma Phase 1/2 study with seclidemstat SP-3164 targeted protein...